1. Introduction
===============

Hypertension is prevalent and remains one of the most significant causes of mortality worldwide. Elevated blood pressure (BP) is a major risk factor for coronary artery disease and its complications, heart failure, stroke, renal insufficiency, and blindness in diabetic patients. The Global Burden of Disease study estimated that hypertension is now the leading risk factor for disability-adjusted life years worldwide.^\[[@R1]\]^ The risk of developing hypertension can be reduced by effective medication therapy management and significant lifestyle modifications. Adherence to antihypertensive medications is the cornerstone for achieving hypertension control.

Nonadherence to medication is a growing concern and is associated with adverse outcomes. Maintaining medication adherence to multiple medications is a complex issue in patients with chronic diseases, particularly cardiovascular diseases (CVDs). The influence of nonadherence to antihypertensive medications is the most important cause of uncontrolled BP. Consequently, because of nonadherence, most (nearly 3-quarters) of the hypertensive patients do not achieve optimal BP control.^\[[@R2]\]^

Several approaches were tried to investigate the medication-taking behavior and the traditional methods such as pill counts, clinical reports, prescription refills and patient-reported measures are some of the cheap and acceptable ones to provide medication adherence information. However, self-reported questionnaires were often used to assess the medication adherence in chronic disease patients. Several self-reported validated questionnaires were developed to monitor medication adherence in chronic disease patients including hypertension patients. Some of the scales suitable for measuring adherence in hypertension patients include Morisky medication adherence scale-8 (MMAS-8),^\[[@R3]\]^ Brief Medication Questionnaire by Svarstad et al,^\[[@R4]\]^ the Hill-Bone Compliance scale,^\[[@R5]\]^ and the most recent Adherence scale by Culig et al.^\[[@R6]\]^ Of these, MMAS-8 remains the best known and most widely used scale for investigating medication adherence in hypertensive patients. To date, there has been no systematic review or meta-analysis conducted to estimate the nonadherence status in hypertensive patients using any of the above-mentioned self-reported scales. Therefore, a better understanding of these issues could help to tailor effective interventions and strategies to improve the medication adherence in hypertensive patients. In order to gather the data from all the available literature that evaluated the adherence to antihypertensive medications using MMAS-8, we aimed to perform a systematic review and meta-analysis to synthesize medication nonadherence in hypertensive patients.

2. Materials and methods
========================

2.1. Search strategies
----------------------

A computerized systematic search of the PubMed, Scopus, and Google Scholar using the Cochrane guidelines to conduct the meta-analysis following PRISMA (Preferred Reporting Items for Systematic review and Meta-Analysis) statement was used (Appendix 1, <https://figshare.com/s/5c111733cd4185c2362a>). Published studies related to antihypertensive medications adherence using MMAS-8 and using MeSH terms: medication adherence^∗^ AND Morisky medication adherence scale^∗^ OR MMAS-8^∗^ AND adherence^∗^ OR compliance^∗^ AND antihypertensive^∗^ AND hypertension^∗^ AND using patients self-reported questionnaire. All the papers that were published in the English language between January 2009 and March 2016 were included. The review was limited to self-reported studies that were conducted using MMAS-8 validated questionnaire administered to the hypertensive patients using antihypertensive medications.

2.2. Inclusion criteria
-----------------------

We included studies that met the following inclusion criteria: Study used the MMAS-8 questionnaire on hypertensive patients to assess the adherence levels to antihypertensive medications; the study was an original article; and studies conducted on hypertensive patients.

2.3. Exclusion criteria
-----------------------

We excluded studies that used the MMAS-8 scale on other than hypertensive patients using antihypertensive medications, the subjects included other CVDs and diabetic patients and the studies using MMAS-4 scale.

2.4. Review process
-------------------

All records that were identified from searches of the electronic databases were loaded into the ENDNOTE software version X5 (Thomson Reuters, Toronto, Ontario, Canada) and duplicates were removed. Two researchers (TMA and ASB) independently screened the titles and abstracts to identify the potentially eligible studies. Studies that were potentially eligible were selected for full-text review (Flow of information). Disagreement was resolved by mutual consent after discussion.

2.5. Data extraction
--------------------

Information on the year of the execution of the study, the geographic location, the sample size, the way of administration of the questionnaire, and data about the nonadherence toward antihypertensive medication were retrieved. In particular, MMAS-8 statements that grouped answers that were scored \<6 were considered as nonadherence outcomes for the meta-analysis.

2.6. Statistical analysis
-------------------------

The meta-analysis was performed using StatsDirect statistical software version 3.0 (Cheshire, UK). The Cochrane Q and the I^2^ were used to evaluate heterogeneity of studies. Random-effects model was used to combine studies showing heterogeneity of Cochrane Q *P* \< 0.10 and I^2^ \> 50.^\[[@R7]\]^ Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) scale was used to assess the quality of the studies by categorizing into high quality (≥75% of the STROBE checklist) and low quality (\<75% of the STROBE checklist).^\[[@R8]\]^ We performed subgroup analysis by gender and studies carried out in different continents. Moreover, Egger and Begg tests representing funnel plots were used to assess the publication bias.

2.7. Ethical statement
----------------------

This study was carried out in strict accordance with the recommendations in the STROBE and PRISMA guidelines. Ethics committee or institutional review board permission is not required for conducting systematic review and meta-analysis.

3. Results
==========

A total of 912 articles were screened from the 3 scientific databases (PubMed = 380, Scopus = 312, and Google Scholar = 220). After screening the abstracts and titles, 852 were excluded because of irrelevance and duplicates. Sixty articles were assessed for full-text review and 32 articles were excluded with reasons (Suppl 2). Finally, 28 articles were included in the systematic review^\[[@R9]--[@R36]\]^ and 25 of these were included in the meta-analysis.^\[[@R9],[@R11]--[@R25],[@R27]--[@R31],[@R33]--[@R36]\]^

3.1. Characteristics of studies assessed
----------------------------------------

In total, 13,688 subjects were included in the analyzed studies. Nine of the studies were conducted in the United States,^\[[@R11],[@R12],[@R15],[@R26],[@R29],[@R30],[@R32],[@R33],[@R35]\]^ and 2 each in China,^\[[@R11],[@R17]\]^ Nigeria,^\[[@R16],[@R22]\]^ Hong Kong,^\[[@R21],[@R25]\]^ and Iran.^\[[@R10],[@R18]\]^ Countries such as Uganda, Lebanon, Kenya, Republic of Korea, Peru, Ethiopia, Ghana, Malaysia, Palestine, Brazil, and Italy were represented with a single study.^\[[@R9],[@R13],[@R19],[@R20],[@R23],[@R24],[@R27],[@R28],[@R31],[@R34],[@R36]\]^ These studies were conducted on hypertensive patients to assess medication adherence using MMAS-8 between January 2009 and March 2016. Twenty-four studies were cross-sectional^\[[@R9]--[@R27]\]^ and others were cohort,^\[[@R35]\]^ observational,^\[[@R36]\]^ and interventional studies.^\[[@R32]\]^ Only 1 randomized controlled trial (RCT) was found.^\[[@R29]\]^ The sample size of studies ranged from 25^\[[@R32]\]^ to 2445^\[[@R21]\]^ subjects. Eleven studies assessed adherence through face-to-face interviews,^\[[@R10],[@R14],[@R18],[@R20],[@R22]--[@R24],[@R26],[@R29]--[@R31]\]^ while 8 studies used self-administered questionnaires,^\[[@R13],[@R17],[@R21],[@R25],[@R32]--[@R34],[@R36]\]^ and only 1 study was administered through a telephone interview.^\[[@R35]\]^ However, 8 studies did not specify the type of MMAS-8 questionnaire administered.^\[[@R9],[@R11],[@R12],[@R15],[@R16],[@R19],[@R27],[@R28]\]^ Except 1 study,^\[[@R22]\]^ all the included studies met the quality criteria and showed high quality (\>75%).^\[[@R9]--[@R27],[@R29]--[@R36]\]^

3.2. Baseline characteristics of study subjects
-----------------------------------------------

The baseline characteristics of 28 studies are presented in Table [1](#T1){ref-type="table"}. Among these hypertensive patients, the majority were females (n = 7859, 57.4%); 34% had comorbidities (n = 4661) and/or uncontrolled hypertension (n = 2606, 19%).

###### 

Overview of studies included in systematic review and meta-analysis (N = 13,688).

![](medi-96-e5641-g001)

3.3. Nonadherence to antihypertensive medications
-------------------------------------------------

We identified a total of 25 studies (n = 12,628) that used MMAS-8 to assess the medication adherence in hypertensive patients. Overall, nonadherence to antihypertensive medications was 45.2% (95% confidence interval \[CI\] = 34.4--56.1, *P* \< 0.001) (Fig. [1](#F1){ref-type="fig"}).

![Nonadherence in hypertensive patients.](medi-96-e5641-g002){#F1}

3.4. Nonadherence in hypertensive patients with comorbidities
-------------------------------------------------------------

Ten studies, with a total of 6836 subjects, reported the medication adherence levels in hypertensive patients with comorbidities. Overall, the nonadherence to antihypertensive medications was significant in hypertensive patients with comorbidities: 31.6% (95% CI = 10.2--97.5), *P* = 0.045; heterogeneity I^2^ = 99.1% (Fig. [2](#F2){ref-type="fig"}).

![Nonadherence in hypertensive patients with comorbidities.](medi-96-e5641-g003){#F2}

3.5. Nonadherence in uncontrolled hypertension patients
-------------------------------------------------------

We identified 10 studies (n = 4574) that reported the medication adherence levels in uncontrolled and controlled hypertension patients. Compared to controlled hypertensive patients (n = 1973) (59.7% \[95% CI = 37.7--81.7\]), nonadherence in uncontrolled hypertensive patients (n = 2606) was 83.7% (95% CI = 59.9--117.0), but no statistical significance was noticed (*P* = 0.2991); heterogeneity I^2^ = 86.2% (Fig. [3](#F3){ref-type="fig"}).

![Nonadherence in uncontrolled hypertension patients.](medi-96-e5641-g004){#F3}

3.6. Subgroup analysis
----------------------

To investigate the potential discrepancy, the results of 25 studies were stratified by gender with regard to nonadherence to antihypertensive medications using a random model. Overall, the risk of nonadherence to antihypertensive medications was 1.3 times (95% CI = 0.99--1.74, *P* = 0.058) higher in male hypertensive patients than females (odds ratio = 0.73, 95% CI = 0.56--0.93) with a relative risk of 0.883 (95% CI = 0.76--1.02), *P* = 0.104 (Fig. [4](#F4){ref-type="fig"}). Indeed, in the subgroup analysis, the percentage of nonadherence to antihypertensive medications was higher in females: 53.9% (95% CI = 49.7--57.9), *P* \< 0.001 than males: 46.2% (95% CI = 42.2--50.2), *P* = 0.020.
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3.7. Sensitivity analysis stratified for different continents
-------------------------------------------------------------

Sensitivity analysis was carried out where the studies were conducted in different continents. Studies carried out in Africa (6 studies; n = 1277) (62.5% \[95% CI = 39.9--85.0\]; *P* \< 0.001) and Asia (8 studies; n = 5917) (43.5% \[95% CI = 35.0--53.0\]; *P* \< 0.001) showed a higher proportion of nonadherence to antihypertensive medications than American studies (9 studies; n = 4982) (36.6% \[95% CI = 24.4--48.8\], *P* \< 0.001)and European studies (2 studies; n = 452) (37.1% \[95% CI = 32.7--41.6\], *P* \< 0.001).

3.8. Publication bias
---------------------

Publication bias was not highlighted in all the analysis and confirmed by the Egger and Begg tests showed funnel plots.

4. Discussion
=============

Several epidemiological studies about medication adherence in hypertensive patients using MMAS-8 were conducted in recent years, making it possible to obtain direct evidence of the nonadherence situation of hypertensive patients. Based on the strict inclusion criteria, we reviewed 28 studies that assessed the antihypertensive medication adherence, we included 25 articles in this meta-analysis including 12,603 subjects, covering 15 countries and different provinces, thus the large population guaranteed the reliability of this study.

Using a systematic review, we aimed to gather different studies published between January 2009 and March 2016 that assessed medication adherence in hypertensive patients using MMAS-8. To our knowledge, this is the first systematic review on this topic. Previous reviews were focused on beliefs and hypertension treatment,^\[[@R37]\]^ nonadherence in resistant hypertension patients,^\[[@R38]\]^ and medication compliance in resistant hypertension patients.^\[[@R39]\]^

4.1. Strengths and limitations
------------------------------

The strengths of this paper consisted of execution of nonadherence to antihypertensive medications by including 25 studies in meta-analysis. This has helped us gather and strengthen the combination of each study findings to obtain pooled prevalence provided stronger evidence about medication nonadherence in hypertensive patients. In addition, the analysis conducted on 5 different outcomes showed interesting results. However, our search strategy was comprehensive, included research articles using MMAS-8 questionnaire, conducted on hypertensive patients and studies published in English language.

4.2. Summary of study findings
------------------------------

Through this study, we identified that a significant number (45.2%) of the hypertensive patients are nonadherent to antihypertensive medications and nearly one-third (31.2%) of hypertensive patients with various comorbidities showed nonadherence to medications. Interestingly, a higher proportion (83.7%) of uncontrolled hypertensive patients was nonadherent to medications. Although a higher percentage (54%) of nonadherence to antihypertensive medications was noticed in females (*P* \< 0.001), the risk of nonadherence was 1.3 times higher in males, with a relative risk of 0.883. Overall, nearly two-thirds (62.5%) of the medication nonadherence was noticed in Africans and Asians (43.5%).

The findings of our review pointed out that the lack of medication adherence in hypertensive patients is a significant concern. "For instance, nearly half (45%) of the hypertensive population studied are nonadherent to antihypertensive medications." This is comparably similar with Carrea et al study findings (57%) assessed the antihypertensive medication adherence using MMAS-8 items and urine fluorescence in resistant hypertensive patients.^\[[@R40]\]^ Nonadherence to pharmacological agents in hypertensive patients has a negative impact and increases the risk of cardiovascular events and stroke. Medication nonadherence is multifactorial, several studies have demonstrated the association between nonadherence and patients' beliefs, socioeconomic status, health literacy, race/ethnicity, and others.^\[[@R37],[@R41]--[@R45]\]^ Early identification of patients' barriers by sharing the concerns with health professionals can help improve adherence, reduce costs, optimize drug therapy, and achieve BP control. However, several interventions were extensively tried to improve the adherence, it is notable that these interventions focused only on implementation of medication adherence for BP control. Future investigations should explore the potential benefits of tailoring patient-specific interventions, implementation adherence versus persistence outcomes, and the preferences for interventional delivery (e.g., face-to-face vs technology-mediated). These interventions were also confirmed by Conn et al review.^\[[@R46]\]^

BP lowering in hypertensive patients with comorbidities is significantly important in reducing vascular risk such as CVDs, coronary heart disease (CHD), stroke, diabetes, heart failure, and chronic kidney disease. However, a few studies identified hypertensive patients with comorbidities and the number of medications prescribed are the 2 significant factors associated with poor adherence.^\[[@R45],[@R47],[@R48]\]^ In contrast, our findings showed that only one-third (31.2%) of hypertensive patients with comorbidities showed nonadherence to antihypertensive medications and was not strongly associated for nonadherence (*P* = 0.045). Evidence from the recent meta-analysis suggests that a 10 mm Hg reduction in systolic BP in hypertensive patients reduces the risk of major CVD events by 20%, CHDs by 17%, stroke by 27%, heart failure by 28%, and all-cause mortality by 13%.^\[[@R49]\]^ This highlights the protective effects of pharmacologically induced BP reduction in hypertensive patients with comorbidities. Despite this, identifying best approach to reduce BP in hypertensive patients with comorbidities remains controversial.^\[[@R50]\]^

Uncontrolled systolic and diastolic BPs are important risk factors for increased cerebrovascular events, cardiovascular events, and all-cause mortality. Studies estimated that more than 50% of the uncontrolled hypertensive patients have suboptimal adherence.^\[[@R51]\]^ Through our investigation we identified an alarming levels of nonadherence to antihypertensive medications in uncontrolled BP patients (83.7% \[95% CI = 59.9--117.0\]) than controlled BP patients (59.7% \[95% CI = 37.7--81.7\]). These results were comparably much higher than de Oliveira-Filho et al study assessed the medication adherence using MMAS-8 showed nearly two-thirds (62.4%) of the uncontrolled BP patients are nonadherent to antihypertensive medications.^\[[@R52]\]^ In order to improve their medication adherence, practitioners need to focus on treatment targets and pharmacists should spend more time to adequately counsel about treatment and comprehensively discuss the advantages of lifestyle modifications in uncontrolled BP patients (but also controlled BP patients).

Antihypertensive medication adherence can vary substantially between individuals, identification of sex differences for nonadherence could assist the healthcare providers to customize an effective intervention. Through a subgroup analysis, our investigation showed nonadherence to antihypertensive medications is 1.3 times higher in male than in female patients, with a relative risk of 0.883 (95% CI = 0.76--1.02), *P* = 0.104. However, the percentage of nonadherence was noticeably higher in females than in males (53.9% vs 46.2%). These results were much higher than Holt et al study conducted on older adult hypertensive patients using MMAS-8, where a higher percentage of women had low adherence scores compared to men (15% vs 13.1%).^\[[@R53]\]^ In accordance with previous studies, no differences in low medication adherence was noticed between men and women in CoSMO study.^\[[@R54]\]^ Further research is needed to better understand the underlying and modified risk factors associated with nonadherence between the sexes.

The sensitivity analysis stratified for different continents showed a significant nonadherence levels in hypertensive patients. In particular, studies carried out in Africa showed a higher percentage of nonadherence levels (62.4%) than Asians (43.5%), Europeans (36.6%), and Americans (36.6%). These findings were consistent with studies conducted in African countries such as Ivory Coast (87.5%), Togo (83.7%), Congo (78.8%), and Tunisia (63.4%).^\[[@R55]--[@R58]\]^These oceanic discrepancies may be due to differences in the populations studied, ethnic/race differences, samples seize, difference in the questionnaire administered, or patients' beliefs.

4.3. Limitations
----------------

The overall quality of the included studies was high, especially given that more than 90% of the studies were assessed as low risk of sampling bias. High level of heterogeneity was noticed across the included studies was one of the limitations of our study. A substantial proportion of the heterogeneity across studies could be due to differences in the population characteristics, sociocultural variations, and study methodologies. In addition, we used only validated and commonly used MMAS-8 questionnaire administered to hypertensive patients in all studies to prevent selection bias. Quality assessment and stratification of the quality and geographic criteria have allowed the evaluation of the presence of potential bias and confounders. Further, we may have missed some potentially relevant studies; however, this systematic review arguably constitutes the largest study on nonadherence to antihypertensive medications comprising \>13,000 participants.

5. Conclusion
=============

This comprehensive meta-analysis of nonadherence to antihypertensive medication documented a significantly higher proportion (45.2%) of medication nonadherence was noticed among hypertensive patients, particularly uncontrolled BP patients (83.7%). There is a need for tailoring interventions by linking adherence behavior with daily habits, developing patient-specific interventions, providing motivational interviews, and actively engaging family members to improve the antihypertensive medication adherence. Future research should explore alternative techniques to assess and monitor the medication adherence program particularly for older adult hypertensive patients.
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